Palo Alto Investors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001306923

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2026 · 56 positions · Total reported value $672.15M · Top-10 concentration 59.9% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 51.8% · 4 new · 25 cut · 0 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -2.7% · vs SPY -4.8% · Prev Value $723.72M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.2% · vs SPY -5.3% · Latest Value $672.15M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Palo Alto Investors LP disclosed 56 equity positions with a combined reported value of $672.15M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 59.9% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PTCT ($56.71M), IOVA ($51.45M), INSM ($50.64M). By sector, the heaviest allocations are Health Care 99.8%, Financials 0.2%.

Versus the prior quarter, Palo Alto Investors LP opened 4 new positions, trimmed 25 and fully exited 0, a turnover rate of 51.8% of positions. The portfolio's overlap with the prior quarter was 93% of names.

The largest new positions opened in Q3 2026 were TARA ($3.16M), CTNM ($2.96M), ANL ($2.39M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • TARA PROTARA THERAPEUTICS INC · $3.16M
  • CTNM CONTINEUM THERAPEUTICS INC · $2.96M
  • ANL ADLAI NORTYE GROUP LTD · $2.39M
  • HELP CYBIN INC · $892.67K

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Palo Alto Investors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Palo Alto Investors LP, based in Palo Alto, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 56 positions worth $672.15M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: PALO ALTO, CA, United States
  • SEC registration: 801-58166 (status: Approved), registered 2000-12-05
  • Regulatory AUM (Form ADV): $696.00M as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 6 private funds, of which 6 hedge funds
  • Website: pa-investors.com

Portfolio Structure

  • 56 positions · $672.15M reported value (Q3 2026)
  • Top 10 holdings = 59.9% of reported value
  • Largest position: PTCT (PTC THERAPEUTICS INC) at 8.4%
  • Average position size: $12.00M

Sector Tilt

  • Health Care 99.8%
  • Financials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 4 new, 10 added, 25 reduced
  • 17 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund reduced positions in 7 of its top-10 holdings (mostly biotech/healthcare) while adding 3, suggesting a cautious stance on existing large caps but selective new bets. 2. Key moves: - Reduced: PTCT (-4.7% shares), IOVA (-34.5% shares), ACAD (-13.2% shares), BMRN (-5.9% shares), UTHR (-5.9% shares), BIIB (-5.2% shares), ANAB (-1.4% shares). - Added: INSM (+7.2% shares), MIRM (+11.0% shares), DYN (+14.2% shares). 3. Portfolio structure: Active, concentrated (56 positions), heavily biased toward Health Care (biotech/pharma), with moderate risk appetite (mix of established and mid-cap names). 4. Per-holding one-liner: - PTCT: PTC Therapeutics (biopharma, unverified). - IOVA: Iovance Biotherapeutics (cancer immunotherapy, unverified). - INSM: Insmed (pulmonary diseases, unverified). - ACAD: Acadia Pharmaceuticals (CNS disorders, unverified). - BMRN: BioMarin (genetic therapies, unverified). - MIRM: Mirum Pharmaceuticals (liver diseases, unverified). - UTHR: United Therapeutics (pulmonary/hematology, unverified). - DYN: Dyne Therapeutics (muscular diseases, unverified). - BIIB: Biogen (neurology, unverified). - ANAB: AnaptysBio (autoimmune/inflammation, unverified). 5. Style summary: Rotating from large-cap biotech to smaller-cap clinical-stage names while trimming exposure across most top holdings.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 11:30

Sector Allocation

Health Care 99.8%
Financials 0.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 875.35K $56.71M 8.44%
8.44%
Reduce
2 3.47M $51.45M 7.65%
7.65%
Reduce
3 443.64K $50.64M 7.53%
7.53%
Add
4 2.49M $50.09M 7.45%
7.45%
Reduce
5 642.46K $38.55M 5.74%
5.74%
Reduce
6 387.31K $33.11M 4.93%
4.93%
Add
7 58.88K $31.90M 4.75%
4.75%
Reduce
8 1.88M $30.32M 4.51%
4.51%
Add
9 132.92K $30.02M 4.47%
4.47%
Reduce
10 595.26K $29.92M 4.45%
4.45%
Reduce
11 424.60K $27.60M 4.11%
4.11%
Reduce
12 741.10K $26.26M 3.91%
3.91%
Add
13 396.53K $25.96M 3.86%
3.86%
Reduce
14 1.21M $19.30M 2.87%
2.87%
Reduce
15 689.34K $12.83M 1.91%
1.91%
Add
16 2.81M $11.89M 1.77%
1.77%
Reduce
17 596.36K $11.21M 1.67%
1.67%
Reduce
18 343.10K $11.12M 1.65%
1.65%
Reduce
19 710.03K $10.67M 1.59%
1.59%
Add
20 1.13M $9.46M 1.41%
1.41%
Reduce
21 158.95K $9.36M 1.39%
1.39%
Reduce
22 203.68K $8.25M 1.23%
1.23%
Reduce
23 7.15M $7.43M 1.11%
1.11%
Add
24 200.98K $6.68M 0.99%
0.99%
Reduce
25 1.34M $6.51M 0.97%
0.97%
Reduce
26 1.16M $6.08M 0.91%
0.91%
Reduce
27 548.07K $5.19M 0.77%
0.77%
Add
28 31.39K $4.56M 0.68%
0.68%
Hold
29 162.87K $3.96M 0.59%
0.59%
Add
30 1.04M $3.16M 0.47%
0.47%
New
31 220.23K $2.96M 0.44%
0.44%
New
32 33.64K $2.90M 0.43%
0.43%
Hold
33 325.48K $2.62M 0.39%
0.39%
Add
34 18.12K $2.57M 0.38%
0.38%
Hold
35 250.00K $2.47M 0.37%
0.37%
Hold
36 149.49K $2.39M 0.36%
0.36%
New
37 84.63K $2.20M 0.33%
0.33%
Hold
38 25.56K $2.13M 0.32%
0.32%
Reduce
39 36.95K $2.04M 0.30%
0.30%
Reduce
40 864.28K $2.01M 0.30%
0.30%
Hold
41 30.04K $1.98M 0.29%
0.29%
Reduce
42 19.61K $1.93M 0.29%
0.29%
Hold
43 326.61K $1.83M 0.27%
0.27%
Hold
44 47.90K $1.78M 0.27%
0.27%
Reduce
45 3.98K $1.52M 0.23%
0.23%
Hold
46 115.62K $1.44M 0.21%
0.21%
Hold
47 1.43M $1.02M 0.15%
0.15%
Reduce
48 104.41K $998.16K 0.15%
0.15%
Hold
49 24.50K $995.43K 0.15%
0.15%
Hold
50 1.79K $900.58K 0.13%
0.13%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Historical Backtest (11 quarters)

Avg precision 89% · recall 89% · F1 89% · avg rank error 1.4 · Top-10 turnover 12%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% INSM · FOLD · BMRN · BIIB · UTHR · ACAD · PRTA · RVNC · STAA · ALNY INSM · FOLD · BMRN · BIIB · UTHR · STAA · ACAD · PRTA · IOVA · ALNY
2024-Q2 90% 90% 90% INSM · FOLD · BMRN · BIIB · UTHR · STAA · ACAD · PRTA · IOVA · SRPT INSM · BMRN · FOLD · UTHR · BIIB · STAA · ALNY · ACAD · PRTA · SRPT
2024-Q3 90% 90% 90% INSM · BMRN · FOLD · UTHR · STAA · BIIB · ALNY · ACAD · PRTA · SRPT INSM · FOLD · BMRN · UTHR · BIIB · STAA · ACAD · ALNY · PRTA · IOVA
2024-Q4 80% 80% 80% INSM · FOLD · BMRN · UTHR · BIIB · STAA · ACAD · ALNY · IOVA · PRTA INSM · FOLD · BMRN · UTHR · ACAD · ALNY · BIIB · SRPT · NVCR · PRTA
2025-Q1 80% 80% 80% INSM · FOLD · BMRN · UTHR · ACAD · ALNY · BIIB · SRPT · NVCR · PRTA INSM · BMRN · FOLD · ACAD · UTHR · BIIB · ALNY · PTCT · PRTA · ANAB
2025-Q2 90% 90% 90% INSM · BMRN · FOLD · ACAD · UTHR · BIIB · ALNY · PTCT · PRTA · ANAB INSM · ACAD · BMRN · FOLD · UTHR · BIIB · ALNY · PTCT · ANAB · NVCR
2025-Q3 90% 90% 90% INSM · ACAD · BMRN · FOLD · BIIB · UTHR · ALNY · PTCT · ANAB · NVCR INSM · PTCT · ACAD · FOLD · BMRN · BIIB · UTHR · ANAB · IOVA · NVCR
2025-Q4 90% 90% 90% INSM · PTCT · ACAD · FOLD · BMRN · BIIB · UTHR · ANAB · IOVA · DYN INSM · FOLD · PTCT · ACAD · BMRN · ANAB · BIIB · DYN · UTHR · IRON
2026-Q1 90% 90% 90% INSM · PTCT · FOLD · ACAD · BMRN · ANAB · DYN · BIIB · IRON · UTHR INSM · ACAD · PTCT · BMRN · UTHR · ANAB · MIRM · DYN · BIIB · IRON
2026-Q2 100% 100% 100% INSM · ACAD · PTCT · BMRN · UTHR · ANAB · MIRM · DYN · IRON · BIIB PTCT · ACAD · INSM · MIRM · ANAB · BMRN · DYN · UTHR · IRON · BIIB
2026-Q3 ★ 90% 90% 90% PTCT · ACAD · MIRM · INSM · ANAB · BMRN · DYN · UTHR · IRON · BIIB PTCT · IOVA · INSM · ACAD · BMRN · MIRM · UTHR · DYN · BIIB · ANAB

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings10 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return+4.76%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+21.77%vs benchmark
Barra annualised vol42.1%Model estimate
Realised vol38.7%Annualised in window
Weighted beta0.70Raw exposure
Factor / specific risk41% / 59%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.285.693.0100.4107.910-0110-2311-16Palo Alto Investors LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+4.76%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+21.77%Portfolio − benchmark
Arithmetic return sum+5.60%Difference vs compounded is the cross term
Weighted raw beta0.70Weighted holding betas
Realised volatility (annualised)38.75%Daily returns in window
Barra model volatility (annualised)42.10%Factor + specific
Factor share of variance41.3%Barra factors
Specific share of variance58.7%Stock residuals
Reported value$107.5M13F long US equity

2. Return attribution

The +5.60% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +2.37% 42.3%
Momentum & Growth 3 -0.15% -2.7%
Volatility & Tail Risk 7 +8.23% 146.9%
Industry 12 +6.98% 124.7%
Specific 1 -11.83% -211.2%
Return attribution (style + industry, %)-21.6-10.8+0.0+10.8+21.6Mid Cap-0.48Momentum+0.50Amihud Illiquidity-0.60Growth-0.71Beta-0.75Non-linear Size+1.08Max Drawdown+1.19Leverage (Downside Vol)+1.51Size+2.11Residual Volatility+5.63Health Care+6.98Skewness-8.41Historical Volatility-10.95Kurtosis+20.01
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +2.67 +7.51% +20.01% 357.3%
Health Care Industry +1.00 +6.98% +6.98% 124.7%
Residual Volatility Style +1.71 +3.29% +5.63% 100.5%
Size Style -1.08 -1.95% +2.11% 37.6%
Leverage (Downside Vol) Style -0.88 -1.71% +1.51% 27.0%
Max Drawdown Style -0.67 -1.76% +1.19% 21.2%
Non-linear Size Style +1.07 +1.01% +1.08% 19.3%
Momentum Style -0.13 -4.00% +0.50% 8.9%
Turnover Style -0.04 -4.80% +0.18% 3.2%
Liquidity Style +0.24 +0.36% +0.09% 1.6%
Short-term Reversal Style +0.07 +0.87% +0.06% 1.1%
Mid Cap Style +0.25 -1.94% -0.48% -8.7%
Amihud Illiquidity Style +1.35 -0.45% -0.60% -10.7%
Growth Style -0.41 +1.75% -0.71% -12.7%
Beta Style -0.17 +4.44% -0.75% -13.4%
Skewness Style +1.91 -4.39% -8.41% -150.2%
Historical Volatility Style +0.78 -14.00% -10.95% -195.5%
Specific Specific — — -11.83% -211.2%

3. Risk attribution

Annualised volatility is 42.10%; factor risk explains 41.3% of variance and specific risk 58.7%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-63.4-31.7+0.0+31.7+63.4Short-term Reversal-0.34Non-linear Size+0.35Residual Volatility+1.17Size+1.27Amihud Illiquidity+1.73Growth+2.63Historical Volatility+2.84Max Drawdown+3.61Kurtosis+6.63Skewness+6.81Health Care+14.22Specific+58.72
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 58.7% +24.72% 24.7%
Health Care Industry +1.00 14.2% +5.99% 6.0%
Skewness Style +1.91 6.8% +2.87% 2.9%
Kurtosis Style +2.67 6.6% +2.79% 2.8%
Max Drawdown Style -0.67 3.6% +1.52% 1.5%
Historical Volatility Style +0.78 2.8% +1.20% 1.2%
Growth Style -0.41 2.6% +1.11% 1.1%
Amihud Illiquidity Style +1.35 1.7% +0.73% 0.7%
Size Style -1.08 1.3% +0.53% 0.5%
Residual Volatility Style +1.71 1.2% +0.49% 0.5%
Non-linear Size Style +1.07 0.3% +0.15% 0.1%
Short-term Reversal Style +0.07 -0.3% -0.14% -0.1%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.5-0.30.81.93.0Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.08 +2.10 -3.18
Non-linear Size +1.07 +1.68 -0.61
Mid Cap +0.25 +0.13 +0.12
Beta -0.17 +1.29 -1.46
Momentum -0.12 +0.72 -0.84
Short-term Reversal +0.07 -0.64 +0.72
Residual Volatility +1.71 -0.40 +2.11
Historical Volatility +0.78 +0.86 -0.08
Liquidity +0.24 +0.11 +0.13
Amihud Illiquidity +1.35 +1.16 +0.19
Turnover -0.04 +0.21 -0.24
Growth -0.41 +0.58 -0.99
Leverage (Downside Vol) -0.88 +0.14 -1.03
Skewness +1.92 +0.24 +1.68
Kurtosis +2.67 +0.21 +2.45
Max Drawdown -0.67 -0.08 -0.59

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Health Care 100.0% 1.7% +3.92% +8.29% +24.98% -0.08% -4.29% +3.78%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Total +23.98% +15.77% -20.13% +19.62%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
INSM INSMED INC Health Care 47.12% +7.66% +3.61% Add
UTHR UNITED THERAPEUTICS CORP DEL Health Care 29.69% +8.49% +2.52% Reduce
TSHA TAYSHA GENE THERAPIES INC Health Care 6.06% -16.63% -1.01% Reduce
ALGN ALIGN TECHNOLOGY INC Health Care 4.25% +14.19% +0.60% Hold
NAMS NEWAMSTERDAM PHARMA COMPANY Health Care 3.69% -19.98% -0.74% Add
CTNM CONTINEUM THERAPEUTICS INC Health Care 2.75% -27.94% -0.77% New
SGMT SAGIMET BIOSCIENCES INC Health Care 2.30% +2.53% +0.06% Hold
CRSP CRISPR THERAPEUTICS AG Health Care 1.90% -27.02% -0.51% Reduce
HUM HUMANA INC Health Care 1.42% +20.88% +0.29% Hold
MDGL MADRIGAL PHARMACEUTICALS INC Health Care 0.84% -15.87% -0.13% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 INSM Health Care 47.12% +7.66% +3.61%
2 UTHR Health Care 29.69% +8.49% +2.52%
3 ALGN Health Care 4.25% +14.19% +0.60%
4 HUM Health Care 1.42% +20.88% +0.29%
5 SGMT Health Care 2.30% +2.53% +0.06%
6 MDGL Health Care 0.84% -15.87% -0.13%
7 CRSP Health Care 1.90% -27.02% -0.51%
8 NAMS Health Care 3.69% -19.98% -0.74%
9 CTNM Health Care 2.75% -27.94% -0.77%
10 TSHA Health Care 6.06% -16.63% -1.01%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned +4.76%, versus -17.01% for the QQQ synthetic benchmark — an excess of +21.77%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +20.01%, Health Care +6.98%, Residual Volatility +5.63%; the largest drags came from Historical Volatility -10.95%, Skewness -8.41%, Beta -0.75%. Specific (stock-level) return contributed -11.83%.
  3. Risk attribution: Barra model volatility is 42.10% annualised; factor risk explains 41% of variance and specific risk 59%. The largest factor risk sources are Health Care 14.2%, Skewness 6.8%, Kurtosis 6.6%.
  4. Style tilt: size -1.08, momentum -0.12, volatility +0.78, liquidity +0.24; the weighted raw beta is 0.70. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.77% and interaction -20.13%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Palo Alto Investors LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Palo Alto Investors LP reported 56 equity positions worth $672.15M in aggregate; its largest disclosed positions were PTCT ($56.71M), IOVA ($51.45M), INSM ($50.64M).

How large is Palo Alto Investors LP's portfolio?

Palo Alto Investors LP reported $672.15M of long equity holdings across 56 positions as of 2026-Q3. Top-10 holdings account for 59.9% of reported value.

What is Palo Alto Investors LP's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/palo-alto-investors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →